Anti‐VEGF drugs such as lenvatinib or bevacizumab combined with immunotherapy or EGFR inhibitors have shown encouraging results in FH‐deficient renal cell carcinoma, suggesting that they may also derive some benefit for patients with FH‐deficient Leydig cell tumours.139. This evidence concerns the gene EGFR and hereditary clear cell renal cell carcinoma.